MMP10 as a Radioligand Therapy Target
MMP10, matrix metallopeptidase 10, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, MMP10 staining is highest in glioma (100% of samples positive), melanoma (100% of samples positive) and kidney cancer (100% of samples positive). Clinical status: Discovery-stage (no clinical drug program).
Is MMP10 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in glioma, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
MMP10 expression in cancer
Protein expression of MMP10 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Glioma | 0.97 | High | 100% |
| Melanoma | 0.94 | High | 100% |
| Kidney Cancer | 0.92 | High | 100% |
| Lymphoma | 0.78 | High | 92% |
| Head and Neck Cancer | 0.75 | High | 100% |
| Endometrial Cancer | 0.73 | High | 100% |
| Testicular Cancer | 0.72 | High | 100% |
| Bladder Cancer | 0.70 | High | 100% |
| Lung Cancer | 0.69 | High | 100% |
| Thyroid Cancer | 0.67 | High | 100% |
| Cervical Cancer | 0.67 | High | 100% |
| Skin Cancer | 0.58 | High | 83% |
| Ovarian Cancer | 0.52 | High | 73% |
| Pancreatic Cancer | 0.52 | High | 73% |
| Neuroendocrine Tumors | 0.50 | Medium | 100% |
| Colorectal Cancer | 0.50 | Medium | 80% |
| Breast Cancer | 0.50 | Medium | 80% |
| Gastric Cancer | 0.47 | Medium | 75% |
| Prostate Cancer | 0.47 | Medium | 90% |
| Liver Cancer | 0.33 | Medium | 58% |
Is MMP10 internalized?
Nuclens has not yet extracted internalization evidence for MMP10. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
MMP10 clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for MMP10 yet. Search ClinicalTrials.gov for MMP10 trials.
MMP10 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See MMP10 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
MMP10 gene essentiality (DepMap)
CRISPR knockout effect across 1248 cancer cell lines: -0.03 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related glioma radioligand targets
EGFR · HER3 (ERBB3) · c-MET (MET) · ITGAV · B7-H3 (CD276) · SSTR2 · STEAP2 · FAP
See all radioligand therapy targets in glioma.
See how MMP10 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.